Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A National Web-Based Randomized Phase III Study of Erlotinib or Placebo Following Concurrent Docetaxel, Carboplatin, and Thoracic Radiotherapy in Patients With Inoperable Stage III Non-Small Cell Lung Cancer (D0410).

NCT00153803 is registered in ClinicalTrials.gov with Dartmouth-Hitchcock Medical Center as lead sponsor.

NCT NCT00153803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00153803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A National Web-Based Randomized Phase III Study of Erlotinib or Placebo Following Concurrent Docetaxel, Carboplatin, and Thoracic Radiotherapy in Patients With Inoperable Stage III Non-Small Cell Lung Cancer (D0410).
Lead sponsor
Dartmouth-Hitchcock Medical Center
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2005
Completion date
April 30, 2014
Enrollment
245 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, non-small cell lung cancer, nsclc